Intelligent Bio Solutions (NASDAQ:INBS) Stock Rating Upgraded by Wall Street Zen

Intelligent Bio Solutions (NASDAQ:INBS) was upgraded by Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Intelligent Bio Solutions has an average rating of “Sell”.

Intelligent Bio Solutions Stock Down 3.4%

Shares of NASDAQ:INBS opened at $8.69 on Friday. The company’s 50-day moving average price is $8.77 and its 200 day moving average price is $11.70. The company has a market cap of $10.60 million, a PE ratio of -0.51 and a beta of 4.45. Intelligent Bio Solutions has a fifty-two week low of $4.03 and a fifty-two week high of $27.50.

Intelligent Bio Solutions (NASDAQ:INBS) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($3.50) EPS for the quarter, missing the consensus estimate of ($1.50) by ($2.00). Intelligent Bio Solutions had a negative net margin of 330.00% and a negative return on equity of 276.73%. The firm had revenue of $1.11 million during the quarter, compared to analyst estimates of $4.80 million. As a group, equities analysts anticipate that Intelligent Bio Solutions will post -1.25 EPS for the current year.

Institutional Trading of Intelligent Bio Solutions

Hedge funds and other institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC acquired a new position in shares of Intelligent Bio Solutions in the third quarter worth about $435,000. Alyeska Investment Group L.P. lifted its position in shares of Intelligent Bio Solutions by 9.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 673,492 shares of the company’s stock valued at $687,000 after acquiring an additional 59,600 shares in the last quarter. Finally, Warberg Asset Management LLC acquired a new position in Intelligent Bio Solutions in the 3rd quarter worth approximately $46,000. Institutional investors own 32.97% of the company’s stock.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions, Inc, through its wholly owned subsidiary, is focused on the design, development and marketing of rapid, real-time detection and identification systems for foodborne and environmental pathogens. The company’s flagship product, the RAPID-B System, integrates patented biosensor and fluorescence technologies to detect viable microorganisms in a fraction of the time required by traditional culture-based testing methods. This approach enables food processors, beverage producers, environmental testing laboratories and homeland security agencies to identify contaminants such as Escherichia coli O157:H7, Salmonella spp.